Cysview: Who It’s For

Anyone who is suspected of having or is known to have bladder cancer (from a previous cystoscopy) can have BLC with Cysview.

Ideally, it should be used in:

  • first transurethral resection of bladder tumor (TURBT)
  • first follow-up cystoscopy
  • the management of intermediate-risk patients
  • the management of high-risk patients

For use in first TURBT and the management of intermediate and high-risk patients1

Recommended patient types2,3

  • Patients receiving first TURBT because of suspicion of non-muscle invasive bladder cancer (NMIBC)
  • Patients receiving repeat TURBT
  • Patients who received BCG treatment (to assess response after 6 weeks)
  • Patients undergoing surveillance
  • Referred patients (who have not previously had a Blue Light Cystoscopy with Cysview) who will be receiving intravesical therapy when residual disease is suspected
  • Patients with positive cytology and negative White Light Cystoscopy

Cysview may not detect all bladder tumors and is not a replacement for random biopsies.

1 Cysview [prescribing Information]. 2019:1-4.

2 Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Appropriate Use in the USA. Nat Rev Urol. 2014;11(10):589-596.

Lotan Y, Bivalacqua TJ, Downs T, et. al. Blue Light Flexible Cystoscopy with Hexaminolevulinate in Non-Muscle Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Optimal Use in the USA — Update 2018. Nat Rev Urol. 2019;16(6):377-386.

Watch Patient and Caregiver Guide to Bladder Cancer


Dr. Neal Shore
and patient
Cameron Todd

Watch Now